Cita APA

Lima-Posada, I., Stephan, Y., Soulié, M., Bonnard, B., Nicol, L., Kolkhof, P., . . . Palacios Ramírez, R. (2023). Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.

Citación estilo Chicago

Lima-Posada, Ixchel, Yohan Stephan, Matthieu Soulié, Benjamin Bonnard, Lionel Nicol, Peter Kolkhof, Frederic Jaisser, Paul Mulder, y Roberto Palacios Ramírez. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure With Preserved Ejection Fraction. 2023.

Cita MLA

Lima-Posada, Ixchel, et al. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure With Preserved Ejection Fraction. 2023.